Carcinoid Tumor Global Market Report 2025

The carcinoid tumor market size has grown rapidly in recent years. It will grow from $1.61 billion in 2024 to $1.78 billion in 2025 at a compound annual growth rate (CAGR) of 10.7%. The growth during the historic period can be attributed to the rising incidence of neuroendocrine tumors, increased awareness of rare cancers, improvements in healthcare infrastructure, the availability of targeted therapies, and the expansion of clinical trials for new treatment options.

The carcinoid tumor market size is expected to see rapid growth in the next few years. It will grow to $2.65 billion in 2029 at a compound annual growth rate (CAGR) of 10.5%. The growth during the forecast period can be attributed to the rising demand for personalized medicine, a greater focus on early detection and diagnosis, increased adoption of minimally invasive surgeries, expanding research on novel therapies, and the growing use of molecular targeted therapies. Key trends expected in this period include the integration of AI and machine learning in diagnostics, a shift toward combination therapies, the expansion of telemedicine and remote monitoring, a focus on patient-centric care, and increased collaborative research efforts.

The increasing prevalence of obesity is driving the growth of the carcinoid tumor market. Obesity, characterized by a body mass index (BMI) of 30 or higher, is rising due to factors such as poor dietary habits, lack of physical activity, and excessive consumption of processed foods. This condition promotes chronic inflammation, insulin resistance, and the secretion of growth factors that contribute to tumor development, including carcinoid tumors. For example, according to the Centers for Disease Control and Prevention (CDC), in 2022, 22 U.S. states reported an adult obesity rate of 35% or higher, up from 19 states in 2021. As obesity rates continue to rise, the incidence of obesity-related cancers, including carcinoid tumors, is expected to increase, further expanding the market.

Advancements in neuroendocrine tumor detection are also playing a crucial role in market growth. Companies are developing innovative diagnostic tools, such as fully automated chromogranin A (CgA) tests, to enhance early detection and improve treatment outcomes. In October 2023, Thermo Fisher Scientific received FDA clearance for the Thermo Scientific B·R·A·H·M·S CgA II KRYPTOR immunoassay, the first FDA-approved chromogranin A test. This fully automated test measures CgA levels in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs), helping monitor tumor progression and assess treatment efficacy. By utilizing TRACE technology, the test provides precise results in under 30 minutes, replacing manual laboratory-developed tests and improving diagnostic accuracy and efficiency.

In April 2022, SERB Pharmaceuticals acquired the European commercialization rights for Xermelo (telotristat ethyl) from Ipsen. Xermelo is a treatment for carcinoid syndrome diarrhea, a symptom of carcinoid tumors. This acquisition strengthens SERB’s portfolio of treatments for rare diseases and expands access to improved therapeutic options outside the U.S. and Japan. Ipsen, a France-based biopharmaceutical company, continues to focus on developing treatments for carcinoid syndrome and other rare cancers, contributing to the overall growth of the market.

Major players in the carcinoid tumor market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Sanofi S.A., Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Siemens Healthineers AG, Boston Scientific Corporation, Boehringer Ingelheim International GmbH, Catalent Inc, Ipsen S.A., Exelixis Inc, Novocure Limited, Hutchison MediPharma Limited (A subsidiary of HUTCHMED), Tarveda Therapeutics Inc., Lexicon Pharmaceuticals Inc., and Dauntless Pharmaceuticals Inc.

North America was the largest region in the carcinoid tumor market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in carcinoid tumor report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the carcinoid tumor market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

A carcinoid tumor is a rare, slow-growing neuroendocrine tumor that typically develops in the gastrointestinal tract or lungs. It originates from enterochromaffin cells, which produce and release hormones such as serotonin. Symptoms vary depending on the tumor’s location and whether it secretes hormones, potentially leading to carcinoid syndrome.

The primary types of carcinoid tumors include gastrointestinal neuroendocrine tumors (GI NETs), pancreatic neuroendocrine tumors, lung neuroendocrine tumors, and other disease types. Gastrointestinal neuroendocrine tumors (GI NETs) arise from neuroendocrine cells in the digestive system, with carcinoid tumors being a common, slow-growing subtype. Treatment options include octreotide, lanreotide, telotristat ethyl, capecitabine (Xeloda), 5-fluorouracil (5-FU), doxorubicin (Adriamycin), etoposide (VP-16), dacarbazine (DTIC), streptozocin, and other therapies, administered via oral and parenteral routes. These treatments are distributed through both online and offline channels and are utilized by hospitals, clinics, academic institutions, and research organizations.

The carcinoid tumor market research report is one of a series of new reports that provides carcinoid tumor market statistics, including the carcinoid tumor industry global market size, regional shares, competitors with the carcinoid tumor market share, detailed carcinoid tumor market segments, market trends, and opportunities, and any further data you may need to thrive in the carcinoid tumor industry. This carcinoid tumor market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The carcinoid tumor market consists of revenues earned by entities by providing services such as pharmaceutical treatment, radiation therapy, diagnostic services, and surgical interventions. The market value includes the value of related goods sold by the service provider or included within the service offering. The carcinoid tumor market also includes sales of diagnostic tools, pharmaceuticals, chemotherapy agents, radiopharmaceuticals, and supportive care products. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.